Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Pieris Pharma (NQ: PIRS )

0.8500 +0.0021 (+0.25%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 1, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 3,708,199
Open 0.8500
Bid (Size) 0.8303 (3)
Ask (Size) 0.8900 (10)
Prev. Close 0.8479
Today's Range 0.8200 - 0.8975
52wk Range 0.7181 - 2.115
Shares Outstanding 82,019,103
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Pieris Pharmaceuticals Announces Presentation of Encouraging Preclinical Data for PRS-400 at ATS 2023 International Conference
Via ACCESSWIRE
Pieris Pharmaceuticals Announces Presentation of Promising Preclinical Data for PRS-220 at ATS 2023 International Conference
Via ACCESSWIRE

Performance

YTD
-22.02%
-22.02%
1 Month
+14.25%
+14.25%
3 Month
-42.95%
-42.95%
6 Month
-12.87%
-12.87%
1 Year
-52.25%
-52.25%

More News

Read More
Pieris Pharmaceuticals: Q1 Earnings Insights
Via Benzinga
Recap: Pieris Pharmaceuticals Q1 Earnings
Via Benzinga
Pieris Pharmaceuticals Reports First Quarter 2023 Financial Results and Business Updates
Via ACCESSWIRE
Preview: Pieris Pharmaceuticals's Earnings
Via Benzinga
Pieris Pharmaceuticals Reports Full-Year 2022 Financial Results and Business Updates
Via ACCESSWIRE
Recap: Pieris Pharmaceuticals Q3 Earnings
Via Benzinga
Pieris Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update
Via ACCESSWIRE
Pieris Pharmaceuticals Announces Successful Completion of Safety Review for 10 mg Dose of Phase 2a Trial of Elarekibep (PRS-060/AZD1402)
Via ACCESSWIRE
Pieris Pharmaceuticals to Host First Quarter 2023 Investor Call and Provide Corporate Update on May 10, 2023
Via ACCESSWIRE
Pieris Pharmaceuticals Announces Presentation of Positive Clinical Data for Cinrebafusp Alpa (PRS-343) At 2023 AACR Annual Meeting
Via ACCESSWIRE
Pieris Pharma Pushes Elarekibep Data Readout, Investors React Negatively
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Why Kodiak Sciences Shares Are Trading Higher By 18%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Pieris Pharmaceuticals to Host Year End 2022 Investor Call and Provide Corporate Update on March 29, 2023
Via ACCESSWIRE
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
Pieris Pharmaceuticals Announces $5 Million Milestone from Seagen for Initiation of Phase 1 Trial of CD228 x 4-1BB Bispecific Molecule (Mabcalin SGN-BB228 (PRS-346)
Via ACCESSWIRE
Pieris Pharmaceuticals To Present at Evercore ISI Healthconx Conference
Via ACCESSWIRE
Pieris Pharmaceuticals to Present at Jefferies London Healthcare Conference
Via ACCESSWIRE
Pieris Pharmaceuticals Announces Dosing of First Subject in Phase 1 Trial of Inhaled CTGF Inhibitor PRS-220
Via ACCESSWIRE
Pieris Pharmaceuticals To Host Third Quarter 2022 Investor Call and Provide Corporate Update on November 2, 2022
Via ACCESSWIRE
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Pieris Pharmaceuticals to Present at H.C. Wainwright 24th Annual Global Investment Conference
Via ACCESSWIRE
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.